Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.41 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 2/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26778859 | 0.80 | LMNA (0.37) | GDAACHESLC6A5MAPTPRKACA | |
| SCHEMBL26778817 | 0.80 | FFAR2 (0.44) | GDAACHESLC6A5MAPTPRKACA | |
| SCHEMBL26779024 | 0.80 | SLC6A5 (0.40) | GDAACHESLC6A5MAPTPRKACA | |
| SCHEMBL26779045 | 0.79 | SLC6A5 (0.42) | GDAACHESLC6A5MAPTAKT2 | |
| SCHEMBL28299580 | 0.78 | ACHE (0.38) | GDAACHESLC6A5MAPTPRKACA | |
| SCHEMBL28198723 | 0.78 | ACHE (0.38) | GDAACHESLC6A5MAPTPRKACA | |
| SCHEMBL3918824 | 0.77 | ENPP1 (0.42) | SLC6A5MAPTPRKACABRD4CYP1A2 | |
| SCHEMBL27051002 | 0.76 | SLC6A5 (0.43) | GDAACHESLC6A5MAPTCYP1A2 | |
| SCHEMBL13354614 | 0.76 | GDA (0.47) | GDAACHESLC6A5MAPTPRKACA | |
| SCHEMBL10217112 | 0.76 | FFAR2 (0.40) | GDAACHESLC6A5MAPTPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1039 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120060265-A | Aptamer, pharmaceutical composition thereof, and method for preventing or treating BCMA-related disease or disorder | 安达贝施医药有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-20250171787-A1 | APTAMERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR PREVENTING OR TREATING BCMA-ASSOCIATED DISEASES OR CONDITIONS | Aptapeutics Limited (CN) | 2025-05-29 | — | — | US | claimed |
| EP-3013958-B1 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS | US HEALTH (US) | 2019-12-25 | — | — | EP | claimed |
| US-10077446-B2 | Glucan-encapsulated siRNA for treating type 2 diabetes mellitus | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2018-09-18 | — | — | US | claimed |
| US-9885035-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2018-02-06 | — | — | US | claimed |
| US-20160138028-A1 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS | UNIVERSITY OF MASSACHUSETTS | 2016-05-19 | — | — | US | claimed |
| EP-3013958-A1 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2016-05-04 | — | — | EP | claimed |
| WO-2014210041-A1 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICE (US) | 2014-12-31 | — | — | WO | claimed |
| WO-2013181553-A2 | DETECTION OF MYCOPLASMA IN CELL CULTURES AND CELL CULTURE DERIVED BIOLOGICALS | AKRON BIOTECH (US) | 2013-12-05 | — | — | WO | claimed |
| WO-2010144295-A1 | APTAMER-TARGETED COSTIMULATORY LIGAND APTAMER | UNIVERSITY OF MIAMI (US) | 2010-12-16 | — | — | WO | claimed |
| WO-2001079487-A2 | POLYDESOXYRIBONUCLEOTIDES FOR INHIBITING THE EXPRESSION OF THE ICAM-1-GENE | DEGITZ KLAUS KARL (DE) | 2001-10-25 | — | — | WO | claimed |
| US-20260125680-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION | MASSACHUSETTS GEN HOSPITAL (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4733400-A1 | ANTISENSE OLIGONUCLEOTIDE TARGETING HIC-5 | SHOWA Medical University (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4729130-A2 | LIPOSOMAL PARTICLES, METHODS OF MAKING SAME AND USES THEREOF | Northwestern University (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4728075-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOE | Leal Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-0616612-A4 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE. | GILEAD SCIENCES INC (US) | 1995-01-11 | — | — | EP | disclosed |
| WO-1994024144-A2 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES | GILEAD SCIENCES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0616612-A1 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE | GILEAD SCIENCES, INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| WO-1993024507-A1 | CONFORMATIONALLY RESTRAINED OLIGOMERS CONTAINING AMIDE OR CARBAMATE LINKAGES FOR SEQUENCE-SPECIFIC BINDING | GILEAD SCIENCES, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993012135-A1 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE | GILEAD SCIENCES, INC. (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125680-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION | PDCD1LG2, CD274, PDCD1 | PDPK1 1360/4885YTHDC1 431/4885YTHDF2 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.